Dermata Therapeutics, Inc. (DRMAW) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Diego, CA, United States. El CEO actual es Gerald T. Proehl.
DRMAW tiene fecha de IPO 2021-08-13, 8 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $7.57K.
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
